Overweight Clinical Trials

169 recruiting

Overweight Trials at a Glance

360 actively recruiting trials for overweight are listed on ClinicalTrialsFinder across 6 cities in 50 countries. The largest study group is Not Applicable with 177 trials, with the heaviest enrollment activity in Dallas, Houston, and Buenos Aires. Lead sponsors running overweight studies include Eli Lilly and Company, Novo Nordisk A/S, and University of Colorado, Denver.

Browse overweight trials by phase

Treatments under study

About Overweight Clinical Trials

Looking for clinical trials for Overweight? There are currently 169 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Overweight trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Overweight clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 360 trials

Recruiting
Phase 3

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

ObesityOverweight
Kailera1,800 enrolled33 locationsNCT07284875
Recruiting
Phase 2

Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseFatty Liver Disease, NonalcoholicOverweight (BMI > 25)
AB Biotics, SA60 enrolled1 locationNCT07193927
Recruiting
Phase 3

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Obesity With DiabetesOverweight With Diabetes
Kailera1,700 enrolled37 locationsNCT07284901
Recruiting
Not Applicable

Adaptation of Human Brown Adipose Tissue to Calorie Restriction

Obesity and Overweight
Universidad de Granada30 enrolled1 locationNCT06878989
Recruiting
Phase 1

A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults

HealthyOverweight and Obese Adults
Syntis Bio64 enrolled1 locationNCT07307274
Recruiting
Phase 2

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

Healthy VolunteersOverweight
National Institute on Alcohol Abuse and Alcoholism (NIAAA)150 enrolled1 locationNCT03407079
Recruiting
Not Applicable

Dyad Plus Effectiveness/Feasibility

Weight LossPediatric ObesityFamily and Household+2 more
Wake Forest University Health Sciences90 enrolled1 locationNCT04036331
Recruiting
Phase 1

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

ObesityOverweight
Amgen45 enrolled3 locationsNCT07523711
Recruiting
Not Applicable

Hormonal Control of Energy and Macronutrient Intake in Obesity (MEMORY)

ObesityOverweightNormal Weight
Steno Diabetes Center Copenhagen45 enrolled1 locationNCT06752967
Recruiting
Phase 2

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

Overweight or Obesity
Regeneron Pharmaceuticals120 enrolled3 locationsNCT07431086
Recruiting
Phase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

ObesityOverweight
Kailera320 enrolled2 locationsNCT07497880
Recruiting
Phase 2

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Overweight or Obesity and Elevated Liver Fat
Amgen180 enrolled15 locationsNCT07441252
Recruiting
Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Diabetes MellitusObesityOverweight
Novo Nordisk A/S630 enrolled73 locationsNCT07533175
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled36 locationsNCT07351058
Recruiting
Phase 1

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

ObesityOverweight
Novo Nordisk A/S45 enrolled1 locationNCT07525791
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or Overweight
Hoffmann-La Roche2,000 enrolled28 locationsNCT07351045
Recruiting
Phase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Obesity and Overweight
Metsera, a wholly owned subsidiary of Pfizer3,500 enrolled196 locationsNCT07311850
Recruiting
Phase 2

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

ObesityOverweight
Novo Nordisk A/S333 enrolled3 locationsNCT07395687
Recruiting
Phase 1

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

ObesityOverweightDrug Interaction+1 more
Pfizer20 enrolled1 locationNCT07508241